ReviewDrugs2012
Pharmacotherapy for breakthrough cancer pain.
Review in Drugs, 2012. The graph could read no effect estimate from its abstract, so it casts no vote on the map. An erratum has been issued. Cited by 36 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
36 citing papers in PubMed, 1 synthesis or guideline pooled it, 111 citations in OpenAlex.
- Pooled it
- Pharmacokinetics and dose proportionality of fentanyl sublingual spray: a single-dose 5-way crossover study.Clinical drug investigation · 2013Trial
- Establishing an efficacy hierarchy for breakthrough cancer pain management: a network meta-analysis of rapid-onset fentanyl formulations and morphine.BMC medicine · 2026Article
- Breakthrough pain and rapid-onset opioids in patients with cancer pain: a narrative review.Journal of Yeungnam medical science · 2024Article
- Once again... breakthrough cancer pain: an updated overview.Journal of anesthesia, analgesia and critical care · 2023Review
- Multidisciplinary approach, continuous care and opioid management in cancer pain: case series and review of the literature.Drugs in context · 2023Article
- High-rate breakthrough cancer pain and tumour characteristics - literature review and case series.Drugs in context · 2023Review
- Review
- Review
- Effects of age and gender in patients receiving doses of opioids for breakthrough pain proportional to background opioid doses.Supportive care in cancer : official journal of the Multinational Association of Supportive Care in Cancer · 2020Article
- Breakthrough Cancer Pain in Patients Receiving Low Doses of Opioids for Background Pain.The oncologist · 2020Article
- The use of fentanyl in pain management in head and neck cancer patients: a narrative review.British journal of pain · 2018Article
- Episodic Breathlessness in Patients with Advanced Cancer: Characteristics and Management.Drugs · 2018Review
- Characteristics and Treatment of Breakthrought Pain (BTcP) in Palliative Care.Medical archives (Sarajevo, Bosnia and Herzegovina) · 2017Article
- Review
- Review
- The use of low doses of a sublingual fentanyl formulation for breakthrough pain in patients receiving low doses of opioids.Supportive care in cancer : official journal of the Multinational Association of Supportive Care in Cancer · 2017Article
- Cost-effectiveness analysis of oral fentanyl formulations for breakthrough cancer pain treatment.PloS one · 2017Article
- Opioids for management of episodic breathlessness or dyspnea in patients with advanced disease.Supportive care in cancer : official journal of the Multinational Association of Supportive Care in Cancer · 2016Review
- A Korean Nationwide Survey for Breakthrough Cancer Pain in an Inpatient Setting.Cancer research and treatment · 2016Article
Corrections and comments
- Commented on by
- Erratum issued
Authors and funding
1 author at 1 institution in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Breakthrough pain (BTP) is a transient exacerbation of pain that occurs either spontaneously, or in relation to a specific predictable or unpredictable trigger, despite relatively stable and adequately controlled background pain. The principal pharmacological treatment of BTP is represented by the administration of opioids as needed. Oral opioids have traditionally been the only available drugs for BTP. However, the onset and duration of action of oral opioids such as morphine or oxycodone may not be suitable for treating many episodes of BTP that are of short onset and duration. Transmucosal administration of lipophilic substances has gained a growing popularity in recent years due to the rapid effect, clinically observable 10-15 minutes after drug administration, and the non-invasive form. Different technologies have been developed to provide fast pain relief with potent opioid drugs such fentanyl, delivered by non-invasive routes (rapid onset opioids, ROOs). All the studies performed with ROOs have recommended that these drugs should be administered to opioid-tolerant patients receiving doses of oral morphine equivalents of at least 60 mg. These preparations, including oral transmucosal fentanyl citrate, fentanyl buccal tablet, sublingual fentanyl, intranasal fentanyl spray, fentanyl-pectin nasal spray and fentanyl buccal soluble film have shown better efficacy than placebo or oral opioids. Long-term studies have confirmed their efficacy and safety.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.